A083790 Stock Overview
CrystalGenomics Invites Co., LTD., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
CrystalGenomics Invites Co., LTD. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩3,660.00 |
52 Week High | ₩5,950.00 |
52 Week Low | ₩2,455.00 |
Beta | -0.051 |
1 Month Change | -1.08% |
3 Month Change | 31.89% |
1 Year Change | 11.25% |
3 Year Change | -59.56% |
5 Year Change | -68.17% |
Change since IPO | -53.43% |
Recent News & Updates
Shareholder Returns
A083790 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -6.2% | 1.4% | 2.4% |
1Y | 11.2% | 21.6% | 12.2% |
Return vs Industry: A083790 underperformed the KR Biotechs industry which returned 21.6% over the past year.
Return vs Market: A083790 matched the KR Market which returned 12.2% over the past year.
Price Volatility
A083790 volatility | |
---|---|
A083790 Average Weekly Movement | 10.6% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A083790's share price has been volatile over the past 3 months.
Volatility Over Time: A083790's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 68 | Joong-Myung Cho | https://www.cgxinc.com |
CrystalGenomics Invites Co., LTD., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex® (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma.
CrystalGenomics Invites Co., LTD. Fundamentals Summary
A083790 fundamental statistics | |
---|---|
Market cap | ₩274.70b |
Earnings (TTM) | -₩47.09b |
Revenue (TTM) | ₩4.88b |
56.3x
P/S Ratio-5.8x
P/E RatioIs A083790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A083790 income statement (TTM) | |
---|---|
Revenue | ₩4.88b |
Cost of Revenue | ₩3.42b |
Gross Profit | ₩1.46b |
Other Expenses | ₩48.55b |
Earnings | -₩47.09b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -627.45 |
Gross Margin | 29.86% |
Net Profit Margin | -965.29% |
Debt/Equity Ratio | 26.7% |
How did A083790 perform over the long term?
See historical performance and comparison